Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyldopa (Racemic). The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | BLM | P54132 | 4/20 | 0.97 |
| ▸ | HPGD | P15428 | 4/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | POLB | P06746 | 3/20 | 0.97 |
| ▸ | APEX1 | P27695 | 3/20 | 0.97 |
| ▸ | RECQL | P46063 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | GAA | P10253 | 2/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 2/20 | 0.97 |
| ▸ | EGFR | P00533 | 2/20 | 0.97 |
| ▸ | FYN | P06241 | 2/20 | 0.97 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyldopa SCHEMBL5370162 | 1.00 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL30176814 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL1321546 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL34003 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL196981 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL29352376 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL1172822 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL29013197 | 0.97 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL259452 | 0.97 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL11452341 | 0.97 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025385-A1 | L-DOPA amide derivatives and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-02-02 | — | — | US | disclosed |
| US-5071858-A | Antipsychotic benzothiopyranylamines | CIBA-GEIGY CORPORATION (US) | 1991-12-10 | — | — | US | disclosed |
| US-4737496-A | ANXIOLYTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-04-12 | — | — | US | disclosed |
| US-3995058-A | Treatment of ethanol withdrawal symptoms with levodopa | MILES LABORATORIES, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025385-A1 | L-DOPA amide derivatives and uses thereof | SNCA, DBH, PARK7 | ADRA2A 40/4885KDM4E 3395/4885HSD17B10 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.